CAL
CLVS

Capital Analysts LLC’s Clovis Oncology, Inc. CLVS Stock Holding History

Capital Analysts LLC’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,500
Closed -$102K – 827
2020
Q3 		$102K Buy
17,500
+1,000
+6% +$5.98K 0.01% 310
2020
Q2 		$111K Sell
16,500
-1,000
-6% -$7.57K 0.01% 269
2020
Q1 		$111K Buy
17,500
+922
+6% +$7.4K 0.01% 248
2019
Q4 		$173K Buy
16,578
+6,328
+62% +$46K 0.02% 245
2019
Q3 		$40K Buy
10,250
+1,125
+12% +$9.1K ﹤0.01% 414
2019
Q2 		$136K Buy
9,125
+1,000
+12% +$18.1K 0.01% 247
2019
Q1 		$201K Buy
8,125
+7,375
+983% +$185K 0.02% 216
2018
Q4 		$13K Buy
750
+500
+200% +$10.2K ﹤0.01% 445
2018
Q3 		$7K Sell
250
-900
-78% -$34.8K ﹤0.01% 468
2018
Q2 		$52K Buy
1,150
+575
+100% +$28K 0.01% 324
2018
Q1 		$30K Buy
575
+325
+130% +$19K ﹤0.01% 360
2017
Q4 		$17K Sell
250
-1,100
-81% -$76.9K ﹤0.01% 372
2017
Q3 		$111K Buy
+1,350
New +$107K 0.01% 231

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Analysts LLC's CLVS Position: Q4 2020 in Review

Capital Analysts LLC sold out of Clovis Oncology, Inc. (CLVS) in Q4 2020, closing a stake of 17,500 shares — an estimated $102K sold.

Capital Analysts LLC first reported a position in CLVS in Q3 2017 and held it in 13 quarters. The position peaked at $201K in Q1 2019. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

  • Capital Analysts LLC reported no remaining Clovis Oncology, Inc. position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 17,500 Clovis Oncology, Inc. shares in Q4 2020, an estimated $102K.
  • Capital Analysts LLC first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 13 quarters.
  • Capital Analysts LLC's Clovis Oncology, Inc. position peaked at $201K in Q1 2019.
  • 159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.